Long term study points to Teva drug Copaxone safety

More than 80% of patients were still walking without assistance despite a mean MS disease duration of 22 years. Pharmaceutical company Teva Pharmaceutical Industries Ltd. today announced the publication of data from a long term clinical study of Copaxone which highlighted the multiple sclerosis (MS) drug's safety and efficacy. The data was published in the February issue of the journal Multiple Sclerosis.

In the 15-year clinical study, more than 80% of patients were still walking without assistance despite an average MS disease duration of 22 years, and two-thirds of patients had not transitioned to secondary progressive MS.
Source: Globes (extrait)
Sclérose laques